K. Syrigos

3.2k total citations · 1 hit paper
73 papers, 1.9k citations indexed

About

K. Syrigos is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, K. Syrigos has authored 73 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 28 papers in Pulmonary and Respiratory Medicine and 13 papers in Surgery. Recurrent topics in K. Syrigos's work include Lung Cancer Treatments and Mutations (20 papers), Lung Cancer Research Studies (12 papers) and Colorectal Cancer Treatments and Studies (11 papers). K. Syrigos is often cited by papers focused on Lung Cancer Treatments and Mutations (20 papers), Lung Cancer Research Studies (12 papers) and Colorectal Cancer Treatments and Studies (11 papers). K. Syrigos collaborates with scholars based in Greece, United States and United Kingdom. K. Syrigos's co-authors include Anastasios J. Karayiannakis, Nikolaos Ziras, George Samonis, Vassilis Georgoulias, Aris Polyzos, D. Mavroudis, Muhammad Wasif Saif, A. Athanasiadis, Ch. Kouroussis and N. Androulakis and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.

In The Last Decade

K. Syrigos

69 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline

2023 172 citations Anna Falanga, Cihan Ay et al. Annals of Oncology profile →

Peers

Countries citing papers authored by K. Syrigos

Since Specialization

Citations

This map shows the geographic impact of K. Syrigos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Syrigos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Syrigos more than expected).

Fields of papers citing papers by K. Syrigos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Syrigos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Syrigos. The network helps show where K. Syrigos may publish in the future.

Co-authorship network of co-authors of K. Syrigos

This figure shows the co-authorship network connecting the top 25 collaborators of K. Syrigos. A scholar is included among the top collaborators of K. Syrigos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Syrigos. K. Syrigos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Histologic Transformation in Cancer: The Path for Clinical Translation 2025 ·Cancer Discovery ·Ioannis Vathiotis, Avisek Banerjee, Utsav Sen, Felix Carl Saalfeld, Debdatta Halder, Andriani Charpidou, K. Syrigos, Hidehito Horinouchi, Ashutosh Tewari, Mark A. Dawson, Martin Wermke, Triparna Sen	0
2	170P: Real-world (RW) characteristics, treatment (Tx) patterns and biomarker use in patients (pts) with early stage non-small cell lung cancer (ES NSCLC) in Greece: Results of the retrospective INFINITY study 2025 ·Journal of Thoracic Oncology ·Sofia Agelaki, Giannis Mountzios, Anna Koumarianou, (unknown), Helena Linardou, (unknown), (unknown), (unknown), Christos Emmanouilidis, P. Kosmidis, (unknown), D. Bafaloukos, (unknown), Davide Mauri, (unknown), (unknown), (unknown), (unknown), K. Syrigos	0
3	DNA Damage Response Network and Intracellular Redox Status in the Clinical Outcome of Patients with Lung Cancer 2024 ·Cancers ·(unknown), (unknown), Dimitra Stefanou, (unknown), K. Syrigos, Vassilis L. Souliotis	1
4	A non-interventional biomarker study in patients with adenocarcinoma of the lung treated with nintedanib plus docetaxel following progression on chemotherapy and/or immunotherapy: LUME-BioNIS 2024 ·Translational Lung Cancer Research ·Martin Reck, K. Syrigos, Skaidrius Miliauskas, (unknown), Bartomeu Massutí, Hannes Buchner, Alexey V. Salnikov, Robert M. Lorence, (unknown), Thomas Kitzing, Keith M. Kerr	0
5	Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline breakdown → 2023 ·Annals of Oncology ·Anna Falanga, Cihan Ay, Marcello Di Nisio, Grigoris Gerotziafas, Luis Jara‐Palomares, (unknown), Ramón Lecumberri, Mario Mandalà, Anthony Maraveyas, (unknown), M. Sinn, K. Syrigos, Annie Young, Karin Jordan	172
6	Epidemiology and diagnosis of pulmonary embolism in lung cancer patients: is there a role for age adjusted D-dimers cutoff? 2019 ·Journal of Thrombosis and Thrombolysis ·Ioannis Anagnostopoulos, (unknown), (unknown), (unknown), G. Poulakou, K. Syrigos, Loukas Thanos	7
7	PMD115 - THE DIAGNOSTIC METHODS AND COST OF LUNG CANCER IN GREECE 2018 ·Value in Health ·Ioannis Gkiozos, Georgia Kourlaba, (unknown), (unknown), (unknown), K. Syrigos, Nikos Maniadakis	1
8	Immune-related adverse events (irAEs) in advanced NSCLC patients treated with atezolizumab: Safety population analyses from the Ph III study OAK 2017 ·Annals of Oncology ·Diego Cortinovis, Joachim von Pawel, K. Syrigos, Julien Mazières, Rafał Dziadziuszko, Louis Fehrenbacher, Paul Conkling, Jerome H. Goldschmidt, (unknown), Rodolfo Bordoni, Michael P. Kosty, Fadi S. Braiteh, Pei He, M. Ballinger, (unknown), Hina Patel, David R. Gandara	4
9	Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK 2017 ·Annals of Oncology ·Joachim von Pawel, K. Syrigos, Julien Mazières, Diego Cortinovis, Rafał Dziadziuszko, David R. Gandara, Paul Conkling, Jerome H. Goldschmidt, (unknown), Rodolfo Bordoni, Michael P. Kosty, Fadi S. Braiteh, (unknown), M. Ballinger, Herry Patel, (unknown), Louis Fehrenbacher	28
10	Hypersensitivity Reactions to Docetaxel: Retrospective Evaluation and Development of a Desensitization Protocol 2011 ·International Archives of Allergy and Immunology ·Ekaterini Syrigou, (unknown), Ηλίας Κοττέας, Nektaria Makrilia, (unknown), (unknown), Ioannis Gkiozos, (unknown), K. Syrigos	37
11	Emmanuil Kondoleon: pioneer in surgical treatment for lymphedema. 2009 ·PubMed ·Evangelos Dimakakos, Nikolaos Arkadopoulos, K. Katsenis, (unknown), K. Syrigos	2
12	Pharmacogenetics and biomarkers in colorectal cancer 2009 ·The Pharmacogenomics Journal ·Alexios S Strimpakos, K. Syrigos, Muhammad Wasif Saif	19
13	Expression of CC chemokine receptor 7 in tonsillar cancer predicts cervical nodal metastasis, systemic relapse and survival 2007 ·British Journal of Cancer ·(unknown), (unknown), Cathy Corbishley, P. Wilson, Paul D. Dalton, David A. Bray, (unknown), Peter Williamson, (unknown), P. R. Evans, K. Syrigos, Chris Nutting, Yolanda Barbáchano, S. A. Eccles, Kevin J. Harrington	20
14	Biweekly Administration of Docetaxel and Gemcitabine for Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Phase II Study 2007 ·Journal of Chemotherapy ·K. Syrigos, Eleni Karapanagiotou, Andriani Charpidou, (unknown), (unknown), (unknown), (unknown), Niki Georgatou, Charalambos Roussos	13
15	Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group 2007 ·Annals of Oncology ·P. Kosmidis, Haralabos P. Kalofonos, C. Christodoulou, K. Syrigos, Thomas Makatsoris, D. Skarlos, (unknown), C. Nicolaides, Dimitrios Bafaloukos, Aristotelis Bamias, E. Samantas, Nikolaos I. Xiros, Ioannis Boukovinas, George Fountzilas, Meletios Α. Dimopoulos	46
16	Non-small cell lung cancer in the young: a retrospective analysis of diagnosis, management and outcome data. 2006 ·PubMed ·Davide Mauri, George Pentheroudakis, D. Bafaloukos, Dimitrios Pectasides, E. Samantas, (unknown), Haralabos P. Kalofonos, K. Syrigos, G. Klouvas, Pavlos Papakostas, P. Kosmidis, George Fountzilas, Nicholas Pavlidis	43
17	FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) 2006 ·British Journal of Cancer ·John Souglakos, N. Androulakis, K. Syrigos, Aris Polyzos, Nikolaos Ziras, A. Athanasiadis, Stylianos Kakolyris, S. Tsousis, Ch. Kouroussis, L. Vamvakas, A. Kalykaki, George Samonis, D. Mavroudis, Vassilis Georgoulias	277
18	Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study 2004 ·British Journal of Cancer ·Vassilis Georgoulias, Ch. Kouroussis, Athina Agelidou, I. Boukovinas, Ph. Palamidas, (unknown), Aristidis Polyzos, K. Syrigos, M. Veslemes, M. Toubis, Alexandros Ardavanis, (unknown), Ioannis G. Vlachonikolis	51
19	Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery 2001 ·European Journal of Cancer ·D Alexiou, Anastasios J. Karayiannakis, K. Syrigos, Andrew P. Zbar, (unknown), Ioannis Bramis, Christos Tsigris	145
20	Prognostic Significance of Autoantibodies Against Tropomyosin in Patients with Colorectal Adenocarcinoma 1999 ·Hybridoma ·K. Syrigos, Athanasios Charalampopoulos, Kyriaki Pliarchopoulou, (unknown), (unknown), Andreas Manouras, (unknown)	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact